Efzofitimod (ATYR1923)
Pulmonary Sarcoidosis
Key Facts
About aTyr Pharma
aTyr Pharma is translating the groundbreaking discovery of extracellular tRNA synthetase biology into a new class of protein-based therapeutics for fibrosis and inflammation. Its lead asset, efzofitimod, has reported Phase 3 topline results in pulmonary sarcoidosis and is in a Phase 2 study for SSc-ILD, targeting diseases with high unmet need. The company's strategy is to advance its proprietary platform to generate a pipeline of immunomodulators while exploring bispecific antibody opportunities through its Pangu BioPharma subsidiary.
View full company profileAbout aTyr Pharma
aTyr Pharma is translating the groundbreaking discovery of extracellular tRNA synthetase biology into a new class of protein-based therapeutics for fibrosis and inflammation. Its lead asset, efzofitimod, has reported Phase 3 topline results in pulmonary sarcoidosis and is in a Phase 2 study for SSc-ILD, targeting diseases with high unmet need. The company's strategy is to advance its proprietary platform to generate a pipeline of immunomodulators while exploring bispecific antibody opportunities through its Pangu BioPharma subsidiary.
View full company profileTherapeutic Areas
Other Pulmonary Sarcoidosis Drugs
| Drug | Company | Phase |
|---|---|---|
| SM001 (alidornase/Tigerase) | SarcoMed USA | Pre-clinical |
| XTMAB-16 | Xentria | Phase 2 |